Does improved insulin sensitivity by irbesartan at the highest tolerated dose provide a benefit in non-diabetic patients with systolic heart failure already receiving standardized treatment?
- PMID: 23434005
- DOI: 10.1016/j.ijcard.2013.01.175
Does improved insulin sensitivity by irbesartan at the highest tolerated dose provide a benefit in non-diabetic patients with systolic heart failure already receiving standardized treatment?
Keywords: Asymmetric dimethylarginine; Chronic heart failure; Insulin sensitivity; Irbesartan; Systolic blood pressure; Tumor necrosis factor-alpha.
Comment on
-
Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: a randomized double-blinded placebo-controlled study.Int J Cardiol. 2012 Nov 29;161(3):137-42. doi: 10.1016/j.ijcard.2011.07.051. Int J Cardiol. 2012. PMID: 21856022 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
